Tìm theo
BTA9881
Thuốc Gốc
Small Molecule
BTA9881 is a respiratory syncytial virus (RSV) antiviral drug developed by the Australian company Biota Holdings. It is currently in phase I trials.
Dược Lực Học : BTA9881 will be used to stop replication of RSV in an infected patient with the aim of clearing the infection or reducing the clinical impact of the disease. Respiratory syncytial virus (RSV) infects people of all ages, but particularly infants, causing similar symptoms to influenza. In the northern hemisphere, the RSV season usually starts in the fall and runs through the spring. The virus is highly contagious, infecting virtually all infants under the age of two and re-infection is common. For example approximately 50 percent of children will experience two RSV infections by the age of two.
Cơ Chế Tác Dụng : BTA9881 is a respiratory syncytial virus (RSV) antiviral drug developed by the Australian company Biota Holdings. It is currently in phase I trials. BTA9881 is a small molecule fusion glycoprotein inhibitor, designed to specifically inhibit the process by which respiratory syncytial virus (RSV) infects a cell.
Dược Động Học :
▧ Absorption :
Orally available.
Chỉ Định : For the treatment of respiratory syncytial virus infections.
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB05226
... loading
... loading